More than 800 people will be employed at the plant, which will make more Libre sensors than any of the company’s other facilities.

The Kilkenny, Ireland facility will focus on the global manufacturing of sensors for Abbott’s CGM diabetes devices.

Abbott on Nov. 18 held a ceremony to celebrate the official opening of a state-of-the-art manufacturing facility in Kilkenny, ...

Abbott (NYSE: ABT) today marked the official opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland with ...

Abbott announced today that it officially opened a new state-of-the-art manufacturing facility in Kilkenny, Ireland.

FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Digital health company says it is now able to integrate continuous glucose monitoring (CGM) data directly into EHR clinical ...

Abbott's Freestyle Libre 2 and 3 are the first CGMs to receive FDA clearance for use during imaging tests like X-rays, CT ...

However, the impact of combining GLP-1 RA therapy with FreeStyle Libre systems (FSL ... "These findings suggest that the ...

Abbott's FreeStyle Libre 2 and 3 are the first and only patient-applied continuous glucose monitoring (CGM) systems to be ...